Yahoo
NYSE - Delayed Quote USD

Pfizer Inc. (PFE)

28.45 -0.36 (-1.25%)
At close: September 4 at 4:00:57 PM EDT
28.45 0.00 (0.00%)
After hours: September 4 at 7:59:49 PM EDT
Trade Pfizer on Coinbase
Chart Range Bar
Loading chart for PFE

What's happening with PFE?

7m ago
Powered by Yahoo Scout

Pfizer faces a challenging landscape with a mix of growth opportunities and risks from patent expirations. Recent FDA approvals and a solid pipeline in oncology and obesity present potential for recovery, but valuation concerns and dividend sustainability remain critical factors for investors.

Powered by Yahoo Scout
  • Previous Close 28.81
  • Open 28.58
  • Bid 28.44 x 670000
  • Ask 28.45 x 840000
  • Day's Range 28.38 - 28.69
  • 52 Week Range 23.58 - 29.21
  • Volume 23,529,537
  • Avg. Volume 42,320,944
  • Market Cap (intraday) 162.156B
  • Beta (5Y Monthly) 0.30
  • PE Ratio (TTM) 37.43
  • EPS (TTM) 0.76
  • Earnings Date Nov 3, 2026
  • Forward Dividend & Yield 1.72 (5.97%)
  • Ex-Dividend Date Jul 24, 2026
  • 1y Target Est 28.61

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

www.pfizer.com

75,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PFE
20.15%
S&P 500 (^GSPC)
12.75%

1-Year Return

PFE
24.06%
S&P 500 (^GSPC)
18.71%

3-Year Return

PFE
3.57%
S&P 500 (^GSPC)
70.93%

5-Year Return

PFE
20.86%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 15.03B
Earnings -248M
Profit Margin -1.65%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
5B
10B
15B
0.0%
10.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

25.00 Low
28.61 Average
28.45 Current
35.75 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/7/2026
Analyst Guggenheim
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 35 -> 31

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (5yr expected)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    6.80%

  • Return on Assets (ttm)

    5.78%

  • Return on Equity (ttm)

    5.01%

  • Revenue (ttm)

    63.7B

  • Net Income Avi to Common (ttm)

    4.34B

  • Diluted EPS (ttm)

    0.76

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    11.7B

  • Total Debt/Equity (mrq)

    74.25%

  • Levered Free Cash Flow (ttm)

    12.49B

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: